Dr Arthur Hilton Parmentier, MD | |
360 Kingstown Rd, Suite 208, Narragansett, RI 02882-3239 | |
(401) 515-0007 | |
(401) 515-0009 |
Full Name | Dr Arthur Hilton Parmentier |
---|---|
Gender | Male |
Speciality | Psychiatry & Neurology - Psychiatry |
Location | 360 Kingstown Rd, Narragansett, Rhode Island |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1639202351 | NPI | - | NPPES |
20407-7 | Other | RI | BLUE CROSS RHODE ISLAND |
401532 | Other | RI | BLUE CHIP RHODE ISLAND |
59-3317650 | Other | RI | UNITED HEALTH CARE OF NEW |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | MD09179 (Rhode Island) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Arthur Hilton Parmentier, MD 360 Kingstown Rd, Suite 208, Narragansett, RI 02882-3239 Ph: (401) 515-0007 | Dr Arthur Hilton Parmentier, MD 360 Kingstown Rd, Suite 208, Narragansett, RI 02882-3239 Ph: (401) 515-0007 |
News Archive
Researchers from Boston University School of Medicine (BUSM) report that physicians who use an automated, electronic medical record (EMR) tracking system to follow-up on patients with an abnormal Pap test could increase the number of women who achieved diagnostic resolution and have women achieve resolution in less time than using traditional methods. These findings appear in the Journal of General Internal Medicine.
Despite the availability of approximately 25 drugs for the treatment of breast cancer, the unmet need in the global market is vast. To address this drawback, pharmaceutical companies have established a robust pipeline that currently has about 52 drugs in development. While chemotherapy remains the most important class of drugs for breast cancer treatment, the trend toward targeted drugs is on the rise.
New research provides critical insights into how normal breast precursor cells may be genetically vulnerable to develop into cancer. The research is published June 4th in the inaugural issue of Stem Cell Reports, an open-access journal from the International Society of Stem Cell Research published by Cell Press.
An anonymous donor has given $500,000 to conduct large-scale clinical trials and laboratory research on the "PapGene" test, a genomic-based screening test that detects ovarian and endometrial cancers in cervical fluid.
› Verified 1 days ago